ReviewDiscover nano2026
Targeting ubiquitin-dependent mitochondrial autophagy and apoptosis in sarcopenia: the therapeutic potential of phytochemicals.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is a progressive degenerative disease of skeletal muscle closely associated with aging, disuse, and chronic diseases, affecting approximately 10-16% of the global older adult population. Its core pathological basis lies in the disruption of skeletal muscle cell proteostasis and mitochondrial dysfunction. At the molecular level, excessive degradation of structural proteins mediated by the ubiquitin-proteasome system forms an intertwined vicious cycle with the inability of ubiquitin-dependent mitophagy to clear damaged organelles, ultimately triggering irreversible cell death programmes within an oxidative stress and inflammatory microenvironment. Due to the high complexity and molecular crosstalk within this cell fate-determining network, traditional single-target interventions often yield limited therapeutic efficacy. In recent years, phytochemicals (such as polyphenols, flavonoids, alkaloids, and coumarins) have demonstrated significant therapeutic potential in the field of sarcopenia due to their unique multi-target, multi-pathway synergistic regulatory advantages. This article reviews the dual-faceted regulatory mechanisms of ubiquitination in skeletal muscle mitochondrial quality control, protein hydrolysis, and apoptosis escape and provides an analysis of how phytochemicals achieve autophagy-promoting, anti-apoptotic, and anti-degradative skeletal muscle protection. However, oral bioavailability is often below 1%, microbiota-dependent metabolism, and the absence of phase III clinical trials have hindered the translational application of phytochemicals. This paper explores the use of nano-delivery systems to overcome the bioavailability bottleneck of phytochemicals, as well as translational application strategies based on the gut-muscle axis to reshape the in vivo metabolism of natural products. This review aims to provide a solid theoretical foundation for the development of novel phytochemical-derived drugs targeting ubiquitination and apoptosis networks and to chart a course for reversing skeletal muscle ageing and enhancing human healthspan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.